SEARCH

SEARCH BY CITATION

References

  • 1
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34:12251241.
  • 2
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:4152.
  • 3
    Ferrari C, Penna A, Bertoletti A, Valli A, Degli Antoni A, Giuberti T, Cavalli A, et al. Cellular immune response to hepatitis B virus encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145:34423449.
  • 4
    Jung M, Spengler U, Schraut W, Hoffman R, Zachoval R, Eisemburg J, Eichenlaub D, et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol 1991; 13:310317.
  • 5
    Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98:11851194.
  • 6
    Penna A, Del Prete G, Cavalli A, Bertoletti A, D'Elios MM, Sorrentino R, D'Amato M, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997; 25:10221027.
  • 7
    Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181:10471058.
  • 8
    Penna A, Chisari F, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, et al. Cytotoxic T lymphocytes recognize an HLA-A2 restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174:15651570.
  • 9
    Jung M, Hartmann B, Gerlach J, Diepolder H, Gruber R, Schraut W, Gruner N, et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 1999; 261:165172.
  • 10
    Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:13951406.
  • 11
    Bottarelli P, Brunetto M, Minutello M, Calvo P, Unutmaz D, Weiner A, Choo Q, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 104:580587.
  • 12
    Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi M, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98:706714.
  • 13
    Diepolder HM, Zachoval R, Hoffmann RM, Wierenga E, Santantonio T, Jung MC, Eichenlaub D, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346:10061007.
  • 14
    Cramp M, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R, Naoumov N. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients with hepatitis C viremia. Gut 1999; 44:424429.
  • 15
    Gruner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, Hoffmann R, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181:15281536.
  • 16
    Lechner F, Wong D, Dunbar P, Chapman R, Chung R, Dohrenwend P, Robbins G, et al. Analysis of successful immune responses in person infected with hepatitis C virus. J Exp Med 2000; 191:14991512.
  • 17
    Lechmann M, Ihlenfeldt HG, Braunschweiger I, Giers G, Jung G, Matz B, Kaiser R, et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus—positive blood donors without viremia. Hepatology 1996; 24:790795.
  • 18
    Chang K-M, Thimme R, Melpolder J, Oldach D, Pemberton J, Moorhead-Lodis J, McHutchison J, et al. Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection. Hepatology 2001; 33:267276.
  • 19
    Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25:449458.
  • 20
    Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997; 159:10121018.
  • 21
    Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed Khalifa K, Peter T, Mansour H, et al. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology 2001; 121:646656.
  • 22
    Chisari F, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol 1995; 13:2960.
  • 23
    Thomson M, Nascimbeni M, Havert MB, Major M, Gonzales S, Alter H, Feinstone SM, et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 2003; 77:862870.
  • 24
    Cooper S, Erickson A, Adams E, Kansopon J, Weiner A, Chien D, Houghton M, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10:439449.
  • 25
    Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence and disease. Proc Natl Acad Sci U S A 2002; 99:1566115668.
  • 26
    Menne S, Roneker CA, Roggendorf M, Gerin JL, Cote PJ, Tennant BC. Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation. J Virol 2002; 76:17691780.
  • 27
    Webster G, Reignat S, Maini M, Whalley S, Ogg G, King A, Brown D, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanism. Hepatology 2000; 32:11171124.
  • 28
    Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77:6876.
  • 29
    Alberti A, Diana S, Sculard GH, Eddleston AL, Williams R. Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. Br Med J 1978; 2:10561058.
  • 30
    Zibert A, Meisel H, Kraas W, Schulz A, Jung G, Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 1997; 25:12451249.
  • 31
    Grady GF, Lee VA, Prince AM, Gitnick GL, Fawaz KA, Vyas GN, Levitt MD, et al. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis 1978; 138:625638.
  • 32
    Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 1996; 93:1539415399.
  • 33
    Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188:21992204.
  • 34
    Ciurea A, Hunziker L, Klenerman P, Hengartner H, Zinkernagel RM. Impairment of CD4(+) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J Exp Med 2001; 193:297305.
  • 35
    Vento S, Ranieri S, Williams R, Rondanelli E, O'Brien C, Eddleston A. Prospective study of cellular immunity to hepatitis B virus antigens from the early incubation phase of acute hepatitis B. Lancet 1987; 2:119122.
  • 36
    Fong TL, Di Bisceglie AM, Biswas R, Waggoner JG, Wilson L, Claggett J, Hoofnagle JH. High levels of viral replication during acute hepatitis B infection predict progression to chronicity. J Med Virol 1994; 43:155158.
  • 37
    Chen M, Sallberg M, Sonnerborg A, Weiland O, Mattsson L, Jin L, Birkett A, et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology 1999; 116:135143.
  • 38
    Major ME, Mihalik K, Fernandez J, Seidman J, Kleiner D, Kolykhalov AA, Rice CM, et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol 1999; 73:33173325.
  • 39
    Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, Feinstone SM. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002; 76:65866595.
  • 40
    Bassett SE, Brasky KM, Lanford RE. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol 1998; 72:25892599.
  • 41
    Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, Lanford RE. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001; 33:14791487.
  • 42
    Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:46504655.
  • 43
    Rentenaar RJ, Gamadia LE, van DerHoek N, van Diepen FN, Boom R, Weel JF, Wertheim-van Dillen PM, et al. Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest 2000; 105:541548.
  • 44
    Shimizu YK, Weiner AJ, Rosenblatt J, Wong DC, Shapiro M, Popkin T, Houghton M, et al. Early events in hepatitis C virus infection of chimpanzees. Proc Natl Acad Sci U S A 1990; 87:64416444.
  • 45
    Korba BE, Cote PJ, Wells FV, Baldwin B, Popper H, Purcell RH, Tennant BC, et al. Natural history of woodchuck hepatitis virus infections during the course of experimental viral infection: molecular virologic features of the liver and lymphoid tissues. J Virol 1989; 63:13601370.
  • 46
    Berquist KR, Peterson JM, Murphy BL, Ebert JW, Maynard JE, Purcell RH. Hepatitis B antigens in serum and liver of chimpanzees acutely infected with hepatitis B virus. Infect Immun 1975; 12:602605.
  • 47
    Maini MK, Boni C, Ogg GS, King AS, Reignat S, Lee CK, Larrubia JR, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology 1999; 117:13861396.
  • 48
    Urbani S, Boni C, Missale G, Elia G, Cavallo C, Massari M, Raimondo G, et al. Virus-specific CD8(+) lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol 2002; 76:1242312434.
  • 49
    Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, Walker B, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75:55505558.
  • 50
    Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169:34473458.
  • 51
    Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O'Callaghan CA, Steven N, et al. Direct visualization of antigen-specific CD8(+) T cells during the primary immune response to Epstein Barr virus in vivo. J Exp Med 1998; 187:13951402.
  • 52
    Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279:21032106.
  • 53
    Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, Reiser M, et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002; 76:61046113.
  • 54
    Anthony DD, Valdez H, Post AB, Carlson NL, Heeger PS, Lehmann PV. Comprehensive determinant mapping of the hepatitis C-specific CD8 cell repertoire reveals unpredicted immune hierarchy. Clin Immunol 2002; 103:264276.
  • 55
    Crispe IN, Dao T, Klugewitz K, Mehal WZ, Metz DP. The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol Rev 2000; 174:4762.
  • 56
    Barnaba V, Franco A, Alberti A, Benvenuto R, Balsano F. Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature 1990; 345:258260.
  • 57
    Klugewitz K, Blumenthal-Barby F, Schrage A, Knolle PA, Hamann A, Crispe IN. Immunomodulatory effects of the liver: deletion of activated CD4+ effector cells and suppression of IFN-gamma-producing cells after intravenous protein immunization. J Immunol 2002; 169:24072413.
  • 58
    Large M, Kittlesen D, Hahn Y. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol 1999; 162:931938.
  • 59
    Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest 2000; 106:12391249.
  • 60
    Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Leroux-Roels G. Hepatitis B virus surface antigen suppresses the activation of monocytes through interaction with a serum protein and a monocyte-specific receptor. J Gen Virol 2002; 83:12811289.
  • 61
    Biron CA. Interferons alpha and beta as immune regulators—a new look. Immunity 2001; 14:661664.
  • 62
    Ou R, Zhou S, Huang L, Moskophidis D. Critical role for alpha/beta and gamma interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic T cells. J Virol 2001; 75:84078423.
  • 63
    Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001; 75:70597066.
  • 64
    Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002; 99:1566915674.
  • 65
    Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999; 189:821829.
  • 66
    Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290:19721974.
  • 67
    Castet V, Fournier C, Soulier A, Brillet R, Coste J, Larrey D, Dhumeaux D, et al. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol 2002; 76:81898199.
  • 68
    Tan SL, Katze MG. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 2001; 284:112.
  • 69
    Taylor D, Shi S, Romano P, Barber G, Lai M. Inhibition of interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285:107110.
  • 70
    Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001; 13:458464.
  • 71
    Liu ZX, Govindarajan S, Okamoto S, Dennert G. NK cells cause liver injury and facilitate the induction of T cell-mediated immunity to a viral liver infection. J Immunol 2000; 164:64806486.
  • 72
    Kakimi K, Lane TE, Chisari FV, Guidotti LG. Cutting edge: inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. J Immunol 2001; 167:67016705.
  • 73
    Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002; 195:4349.
  • 74
    Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195:3541.
  • 75
    Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938941.
  • 76
    Salazar-Mather TP, Lewis CA, Biron CA. Type I interferons regulate inflammatory cell trafficking and macrophage inflammatory protein 1alpha delivery to the liver. J Clin Invest 2002; 110:321330.
  • 77
    Duncan GS, Mittrucker HW, Kagi D, Matsuyama T, Mak TW. The transcription factor interferon regulatory factor-1 is essential for natural killer cell function in vivo. J Exp Med 1996; 184:20432048.
  • 78
    Whalley SA, Murray JM, Brown D, Webster GJ, Emery VC, Dusheiko GM, Perelson AS. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 2001; 193:847854.
  • 79
    Jilbert A, Wu T, England J, Hall P, Carp N, O'Connel A, Mason W. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J Virol 1992; 66:13771388.
  • 80
    Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J, Mason WS. Woodchuck hepatitis virus infections: very rapid recovery after prolonged viremia and infection of virtually every hepatocyte. J Virol 1994; 68:57925803.
  • 81
    Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284:825829.
  • 82
    Cote PJ, Toshkov I, Bellezza C, Ascenzi M, Roneker C, Ann Graham L, Baldwin BH, et al. Temporal pathogenesis of experimental neonatal woodchuck hepatitis virus infection: increased initial viral load and decreased severity of acute hepatitis during the development of chronic viral infection. Hepatology 2000; 32:807817.
  • 83
    Nakamura I, Nupp JT, Cowlen M, Hall WC, Tennant BC, Casey JL, Gerin JL, et al. Pathogenesis of experimental neonatal woodchuck hepatitis virus infection: chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis factor-alpha messenger RNAs. Hepatology 2001; 33:439447.
  • 84
    Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192:921930.
  • 85
    Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002; 16:583594.
  • 86
    Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, Chisari FV, Guidotti LG. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001; 194:17551766.
  • 87
    Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767811.
  • 88
    Mueller SN, Jones CM, Smith CM, Heath WR, Carbone FR. Rapid cytotoxic T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus. J Exp Med 2002; 195:651656.
  • 89
    Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2:251262.
  • 90
    Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002; 195:335341.
  • 91
    Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, Sasaki Y, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999; 162:55845591.
  • 92
    Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001; 120:512524.
  • 93
    Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001; 97:31713176.
  • 94
    Sarobe P, Lasarte JJ, Casares N, Lopez-Diaz de Cerio A, Baixeras E, Labarga P, Garcia N, et al. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 2002; 76:50625070.
  • 95
    Wang FS, Xing LH, Liu MX, Zhu CL, Liu HG, Wang HF, Lei ZY. Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J Gastroenterol 2001; 7:537541.
  • 96
    Beckebaum S, Cicinnati VR, Dworacki G, Muller-Berghaus J, Stolz D, Harnaha J, Whiteside TL, et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 2002; 104:138150.
  • 97
    Lohr HF, Pingel S, Bocher WO, Bernhard H, Herzog-Hauff S, Rose-John S. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B—restoration by exogenous interleukin-12. Clin Exp Immunol 2002; 130:107114.
  • 98
    Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:11041108.
  • 99
    Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller J, et al. Cellular immune responses persist and humoral responses decreases two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6:578582.
  • 100
    Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, et al. The role of virus-specific CD8+ cells in viral control and liver damage during persistent hepatitis B virus (HBV) infection. J Exp Med 2000; 191:12691280.
  • 101
    He X-S, Rehermann B, Lopez-Labrador FX, Boisvert J, Cheung R, Mumm J, Wedemeyer H, et al. Quantitative analysis of hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A 1999; 96:56925697.
  • 102
    Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996; 98:14321440.
  • 103
    Rosen HR, Miner C, Sasaki AW, Lewinsohn DM, Conrad AJ, Bakke A, Bouwer HG, et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 2002; 35:190198.
  • 104
    Welsh R. Assessing CD8 T cell number and dysfunction in the presence of antigen. J Exp Med 2001; 193:F19F22.
  • 105
    Reignat S, Webster GJ, Brown D, Ogg GS, King A, Seneviratne SL, Dusheiko G, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 2002; 195:10891101.
  • 106
    Milich D, Chen M, Hughes J, Jones J. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160:20132021.
  • 107
    Milich DR, Schodel F, Hughes JL, Jones JE, Peterson DL. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 1997; 71:21922201.
  • 108
    Drake D III, Braciale T. Cutting edge: lipid raft integrity affects the efficiency of MHC class I tetramer binding and cell surface TCR arrangement on CD8+ T cells. J Immunol 2001; 166:70097013.
  • 109
    Wang H, Eckels DD. Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition. J Immunol 1999; 162:41774183.
  • 110
    Frasca L, Del Porto P, Tuosto L, Marinari B, Scotta C, Carbonari M, Nicosia A, et al. Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells. J Immunol 1999; 163:650658.
  • 111
    Rehermann B, Pasquinelli C, Mosier SM, Chisari FV. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest 1995; 96:15271534.
  • 112
    Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Sette A, Penna A, et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994; 180:933943.
  • 113
    Tsai S-L, Chen Y-M, Chen M-H, Huang C-Y, Sheen I-S, Yeh C-T, Huang J-H, et al. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998; 115:954966.
  • 114
    Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 1992; 89:34683472.
  • 115
    Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994; 68:14941500.
  • 116
    Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339344.
  • 117
    Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 1998; 27:223227.
  • 118
    Chang KM, Rehermann B, McHutchison JG, Pasquinelli C, Southwood S, Sette A, Chisari FV. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997; 100:23762385.
  • 119
    Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, Houghton M, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A 1995; 92:27552759.
  • 120
    Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, McKinney D, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15:883895.
  • 121
    Thomson M, Nascimbeni M, Gonzales S, Murthy KK, Rehermann B, Liang TJ. Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus. Gastroenterology 2001; 121:12261233.
  • 122
    Purcell RH, Gerin JL. Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. Am J Med Sci 1975; 270:395399.
  • 123
    Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258:135140.
  • 124
    Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, Cao A, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343:388390.
  • 125
    Celis E, Ou D, Otvos L Jr. Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. J Immunol 1988; 140:18081815.
  • 126
    Ferrari C, Penna A, Bertoletti A, Cavalli A, Valli A, Schianchi C, Fiaccadori F. The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J Clin Invest 1989; 84:13141319.
  • 127
    Desombere I, Gijbels Y, Verwulgen A, Leroux-Roels G. Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines. Clin Exp Immunol 2000; 122:390399.
  • 128
    Weiner AJ, Paliard X, Selby MJ, Medina-Selby A, Coit D, Nguyen S, Kansopon J, et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol 2001; 75:71427148.
  • 129
    Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, Govindarajan S, et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000; 32:618625.
  • 130
    Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994; 91:77927796.
  • 131
    Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM, Feinstone SM, et al. Kinetics of CD4(+) and CD8(+) memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 2003; 77:47814793.
  • 132
    Iwarson S, Wahl M, Ruttimann E, Snoy P, Seto B, Gerety RJ. Successful postexposure vaccination against hepatitis B in chimpanzees. J Med Virol 1988; 25:433439.
  • 133
    Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102:968975.
  • 134
    Boni C, Penna A, Ogg G, Bertoletti A, Pilli M, Cavalli A, Urbani S, et al. Lamivudine treatment can overcome cytotoxic T cell hyporesponsiveness in chronic hepatitis B: new perspective for immune therapy. Hepatology 2001; 33:963971.
  • 135
    Menne S, Roneker CA, Korba BE, Gerin JL, Tennant BC, Cote PJ. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 2002; 76:53055314.
  • 136
    Le Guerhier F, Thermet A, Guerret S, Chevallier M, Jamard C, Gibbs CS, Trepo C, et al. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. J Hepatol 2003; 38:328334.